A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
| 适应症 | Triple Negative Breast Neoplasms |
|---|---|
| 分期 | 1/2期 |
| 申办方 | AstraZeneca |
| 状态 | 进行中（已停止招募） |
| 受试者人数 | 243 人 |
| 干预（药物） | Durvalumab, Capivasertib, Oleclumab, Paclitaxel, Trastuzumab deruxtecan |
| 开始日期 | 2018年12月21日 |
| 完成日期 | 2024年11月29日 |
| 结果公布日 | 2026年2月2日 |
摘要
This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer
Dose Limiting Toxicity (DLT) Events
| Arm 2 | 0 Participants |
|---|---|
| Arm 5 | 0 Participants |
| Arm 6 | 0 Participants |
| Arm 7 | 0 Participants |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- Vitamin D and Physical Activity on Bone Health — University of Rochester
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in T — National Cancer Institute (NCI)
- Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor — National Cancer Institute (NCI)
- Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced — National Cancer Institute (NCI)
- Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information: Adm — University of Colorado, Denver
- Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer — National Cancer Institute (NCI)